Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
A look into newly listed Glencore’s valuation
A new ASX heavyweight with coal, copper and trading exposure.
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
We’ll be watching Muse agent adoption, revenue growth, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,929.60 | 14.60 | -0.16% |
| CAC 40 | 7,838.49 | 29.56 | -0.38% |
| DAX 40 | 25,304.42 | 15.35 | -0.06% |
| Dow JONES (US) | 52,495.88 | 529.85 | 1.02% |
| FTSE 100 | 10,733.00 | 31.69 | -0.29% |
| HKSE | 23,903.46 | 35.72 | 0.15% |
| NASDAQ | 26,424.82 | 6.07 | -0.02% |
| Nikkei 225 | 64,825.54 | 750.12 | 1.17% |
| NZX 50 Index | 13,712.86 | 81.17 | 0.60% |
| S&P 500 | 7,712.57 | 21.84 | 0.28% |
| S&P/ASX 200 | 8,802.40 | 14.50 | -0.16% |
| SSE Composite Index | 3,733.42 | 1.95 | -0.05% |